LakeShore Biopharma
LSB was delisted on the 19th of September, 2025.
14 hedge funds and large institutions have $20.4M invested in LakeShore Biopharma in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
13.77% more ownership
Funds ownership: 0% → 13.77% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$21.8M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$13.8M |
| 3 |
VAM
Valliance Asset Management
Central,
Hong Kong
|
+$8.14M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.9M |
| 5 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$3.81M |
Top Sellers
LSB Hedge Fund Activity: Q1 2023 in Review
14 of the 6,284 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma (LSB) for Q1 2023, worth a combined $20.4M.
Buyers outnumbered sellers: 14 funds opened new LSB positions and 0 closed out — a net gain of 14 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $21.8M.
- 14 institutional investors held LakeShore Biopharma (LSB) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $20.4M of LakeShore Biopharma stock for Q1 2023.
- 14 funds opened new LakeShore Biopharma positions in Q1 2023 and 0 closed out, a net change of +14 holders.
- The largest LakeShore Biopharma buyer in Q1 2023 was OrbiMed, an estimated $21.8M added.
Based on aggregated 13F filings for Q1 2023.